Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials.

Zeng X, Chen J

Open source

DOI
10.3389/fonc.2026.1914121
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1914121,
  title = {Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials.},
  author = {Zeng X and Chen J},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1914121},
  url = {https://doi.org/10.3389/fonc.2026.1914121}
}

RIS

TY  - JOUR
TI  - Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials.
AU  - Zeng X
AU  - Chen J
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1914121
UR  - https://doi.org/10.3389/fonc.2026.1914121
ER  - 

APA

X, Z., & J, C. (2026). Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1914121

Source records